Drug intelligence / Profile preview

Xiao'er Yinlian granules

Development stage: Unknown
Lead developer: Yili Pharmaceutical
Administration: Oral

Overview

Xiao'er Yinlian granules is a Traditional Chinese Medicine (TCM) product developed by Yili Pharmaceutical for the treatment of pediatric acute upper respiratory tract infections (common cold) characterized by the 'wind-heat' pattern. The formulation is designed to clear heat and resolve toxins, addressing symptoms such as fever, sore throat, and cough. It is currently being evaluated in Phase 2 clinical trials in China to determine its safety and efficacy in children aged 7 to 12 years, including those with a history of febrile convulsions. The drug is typically compared against active controls such as pediatric acetaminophen granules in clinical settings.

Brand names: Xiao'er Yinlian granules
Other names: Xiao'er Yinlian Keli小儿银连颗粒

Beyond the preview

Go deeper on Xiao'er Yinlian granules.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xiao'er Yinlian granules.

Explore the full profile